Joseph Catanzaro
Stock Analyst at Mizuho
(3.51)
# 912
Out of 5,090 analysts
97
Total ratings
45%
Success rate
7.43%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Initiates: Outperform | $24 | $18.00 | +33.33% | 3 | Oct 21, 2025 | |
| RVMD Revolution Medicines | Initiates: Outperform | $90 | $78.51 | +14.64% | 3 | Oct 21, 2025 | |
| CLDX Celldex Therapeutics | Initiates: Outperform | $48 | $29.59 | +62.22% | 1 | Oct 21, 2025 | |
| APGE Apogee Therapeutics | Initiates: Outperform | $105 | $75.40 | +39.26% | 1 | Oct 21, 2025 | |
| KYMR Kymera Therapeutics | Initiates: Outperform | $81 | $66.56 | +21.69% | 1 | Oct 21, 2025 | |
| IBRX ImmunityBio | Upgrades: Overweight | $4.25 → $5 | $2.31 | +116.79% | 5 | May 20, 2025 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $2.5 → $5 | $4.09 | +22.25% | 5 | May 15, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Neutral | $7.5 → $6 | $2.22 | +170.27% | 10 | Feb 28, 2025 | |
| SDGR Schrödinger | Maintains: Overweight | $50 → $45 | $18.32 | +145.63% | 3 | Feb 27, 2025 | |
| MRUS Merus | Initiates: Overweight | $84 | $96.20 | -12.68% | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $110 | $122.42 | -10.15% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $38 | $44.40 | -14.40% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $20.24 | -25.89% | 3 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $52 → $53 | $63.10 | -16.00% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $10 | $2.16 | +362.96% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.17 | +1,517.99% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $12.18 | +55.99% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $2.71 | +453.75% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $27.82 | +29.40% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $8.41 | +375.62% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $12.44 | +20.58% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $1.03 | +339.02% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $2.44 | +1,132.03% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.11 | +1,701.80% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $9.88 | +82.19% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $2.24 | +1,018.57% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $5.74 | -69.51% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $23.14 | -13.55% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $2.55 | -41.18% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $10.00 | +1,900.00% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $11.09 | +215.60% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.42 | +4,134.30% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.53 | +612.87% | 3 | Apr 7, 2020 |
Nurix Therapeutics
Oct 21, 2025
Initiates: Outperform
Price Target: $24
Current: $18.00
Upside: +33.33%
Revolution Medicines
Oct 21, 2025
Initiates: Outperform
Price Target: $90
Current: $78.51
Upside: +14.64%
Celldex Therapeutics
Oct 21, 2025
Initiates: Outperform
Price Target: $48
Current: $29.59
Upside: +62.22%
Apogee Therapeutics
Oct 21, 2025
Initiates: Outperform
Price Target: $105
Current: $75.40
Upside: +39.26%
Kymera Therapeutics
Oct 21, 2025
Initiates: Outperform
Price Target: $81
Current: $66.56
Upside: +21.69%
ImmunityBio
May 20, 2025
Upgrades: Overweight
Price Target: $4.25 → $5
Current: $2.31
Upside: +116.79%
CytomX Therapeutics
May 15, 2025
Maintains: Overweight
Price Target: $2.5 → $5
Current: $4.09
Upside: +22.25%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $2.22
Upside: +170.27%
Schrödinger
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $18.32
Upside: +145.63%
Merus
Feb 13, 2025
Initiates: Overweight
Price Target: $84
Current: $96.20
Upside: -12.68%
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $122.42
Upside: -10.15%
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $44.40
Upside: -14.40%
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $20.24
Upside: -25.89%
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $63.10
Upside: -16.00%
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $2.16
Upside: +362.96%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.17
Upside: +1,517.99%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $12.18
Upside: +55.99%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $2.71
Upside: +453.75%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $27.82
Upside: +29.40%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $8.41
Upside: +375.62%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $12.44
Upside: +20.58%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $1.03
Upside: +339.02%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $2.44
Upside: +1,132.03%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.11
Upside: +1,701.80%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $9.88
Upside: +82.19%
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $2.24
Upside: +1,018.57%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $5.74
Upside: -69.51%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $23.14
Upside: -13.55%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $2.55
Upside: -41.18%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $10.00
Upside: +1,900.00%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $11.09
Upside: +215.60%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.42
Upside: +4,134.30%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.53
Upside: +612.87%